GII | IGF | GII / IGF | |
Gain YTD | 15.192 | 14.872 | 102% |
Net Assets | 550M | 7.51B | 7% |
Total Expense Ratio | 0.40 | 0.42 | 95% |
Turnover | 14.00 | 13.00 | 108% |
Yield | 3.00 | 3.10 | 97% |
Fund Existence | 18 years | 18 years | - |
GII | IGF | |
---|---|---|
RSI ODDS (%) | N/A | 4 days ago76% |
Stochastic ODDS (%) | 4 days ago70% | 4 days ago80% |
Momentum ODDS (%) | 4 days ago83% | 4 days ago83% |
MACD ODDS (%) | 4 days ago83% | 4 days ago86% |
TrendWeek ODDS (%) | 4 days ago80% | 4 days ago81% |
TrendMonth ODDS (%) | 4 days ago79% | 4 days ago79% |
Advances ODDS (%) | 25 days ago81% | 7 days ago83% |
Declines ODDS (%) | 5 days ago77% | 20 days ago81% |
BollingerBands ODDS (%) | 4 days ago80% | 4 days ago76% |
Aroon ODDS (%) | 4 days ago76% | 4 days ago80% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
QIS | 22.62 | 0.41 | +1.85% |
Simplify Multi-QIS Alternative ETF | |||
VFMF | 137.29 | 1.09 | +0.80% |
Vanguard US Multifactor ETF | |||
ESML | 42.52 | 0.32 | +0.76% |
iShares ESG Aware MSCI USA Small-Cap ETF | |||
FTXH | 26.31 | N/A | +0.01% |
First Trust Nasdaq Pharmaceuticals ETF | |||
FMCE | 26.35 | N/A | N/A |
FM Compounders Equity ETF |
A.I.dvisor indicates that over the last year, GII has been closely correlated with SRE. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if GII jumps, then SRE could also see price increases.